James McKiernan, MD
Urology · New York, NYNPI 1891804746
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.6%), food and beverage and education — rather than concentrated in one kind of arrangement. Urogen Pharma, Inc. accounts for 63.4% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $2,987 and has fallen 98.8% since, to $35 in 2025.
Across 63 payments — averaging $68.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urogen Pharma, Inc.$3K
- Sumitomo Pharma America, Inc.$249
- Johnson & Johnson$215
- Photocure Inc$191
- Astellas Pharma US Inc$148
- Ambu Inc.$145
- plus $634 from 12 others
Across 16 payments — averaging $257,385 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$2.5M
- Sanofi$1.6M
What the payments were for
- Consulting fees$2,40056%
- Food & beverage$1,88444%
- Education$351%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urogen Pharma, Inc. | 8 | $2,738 |
| Sumitomo Pharma America, Inc. | 11 | $249 |
| Johnson & Johnson | 6 | $215 |
| Photocure Inc | 7 | $191 |
| Astellas Pharma US Inc | 4 | $148 |
| Ambu Inc. | 4 | $145 |
| EDAP Technomed Inc | 1 | $121 |
| AbbVie | 5 | $111 |
| Tolmar Pharmaceuticals, Inc. | 5 | $105 |
| Coloplast | 2 | $95 |
| AstraZeneca | 1 | $35 |
| Hollister Incorporated | 2 | $32 |
| 180 Medical, Inc. | 2 | $28 |
| Boston Scientific | 1 | $28 |
| Urovant Sciences Inc | 1 | $27 |
| Palette Life Sciences, Inc. | 1 | $23 |
| Sagent Pharmaceuticals | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
How this compares
$4,319 in reported general payments places this provider in the 60th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bcg (Tice Strain)Bcg Live | 14 | $7,718 |
| Solifenacin Succinate | 16 | $878 |
| Tamsulosin Hcl | 31 | $704 |
| Finasteride | 13 | $262 |
| Cephalexin | 14 | $101 |
Paid to pharmacies, not to this prescriber.
Other urology in New York
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Ketan BadaniNew York$285K
- Michael GrassoNew York$284K
- Mantu GuptaNew York$229K
- Robin SmithNew York$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.